Dermatomyositis - Pipeline Review, H1 2020

May 2020 | 123 pages | ID: DA6A8F8D742EN
Global Markets Direct

Abstracts

Dermatomyositis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis – Pipeline Review, H1 2020, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 6, 3, 2, 2 and 1 respectively.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Dermatomyositis - Overview
Dermatomyositis - Therapeutics Development
Dermatomyositis - Therapeutics Assessment
Dermatomyositis - Companies Involved in Therapeutics Development
Dermatomyositis - Drug Profiles
Dermatomyositis - Dormant Projects
Dermatomyositis - Discontinued Products
Dermatomyositis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Dermatomyositis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Dermatomyositis - Pipeline by Biocon Ltd, H1 2020
Dermatomyositis - Pipeline by Bristol-Myers Squibb Co, H1 2020
Dermatomyositis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Dermatomyositis - Pipeline by Corbus Pharmaceuticals Inc, H1 2020
Dermatomyositis - Pipeline by CSL Ltd, H1 2020
Dermatomyositis - Pipeline by GNI Group Ltd, H1 2020
Dermatomyositis - Pipeline by Johnson & Johnson, H1 2020
Dermatomyositis - Pipeline by Kezar Life Sciences Inc, H1 2020
Dermatomyositis - Pipeline by NovelMed Therapeutics Inc, H1 2020
Dermatomyositis - Pipeline by Octapharma AG, H1 2020
Dermatomyositis - Pipeline by Pfizer Inc, H1 2020
Dermatomyositis - Pipeline by ReveraGen BioPharma Inc, H1 2020
Dermatomyositis - Pipeline by Viela Bio Inc, H1 2020
Dermatomyositis - Dormant Projects, H1 2020
Dermatomyositis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Dermatomyositis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Biocon Ltd
Bristol-Myers Squibb Co
Chugai Pharmaceutical Co Ltd
Corbus Pharmaceuticals Inc
CSL Ltd
GNI Group Ltd
Johnson & Johnson
Kezar Life Sciences Inc
NovelMed Therapeutics Inc
Octapharma AG
Pfizer Inc
ReveraGen BioPharma Inc
Viela Bio Inc